The total price of common shares alloted to Pfizer is 190 billion won (3000 times in value against the face value of a stock).
Pfizer Korea reported on 6 March that it has recorded a net loss of 611.15 million won last year. This is an extraordinary phenomenon, because it had recorded a net profit of 138 billion won in 2007.
Pfizer Korea lanched into the Korean market in 1969. And this time it recorded its first net loss after 1987.
The main cause of its net loss in 2008 is the expiration of patent for its blockbuster hyperlipidemia drug ‘Lipitor' and anti-hypertensive drug 'Norvasct'.
On the other hand, domestic drugmakes put out Lipitor generics in 2008.
And with Lipitor, Yuhan Corporation recorded sales of 2.2 billion won till July 2008, followed by Dong A Pharmaceutical (sales of 1 billion won) and Hanmi Pharmaceutical (sales of 700 million won).<헬스코리아뉴스>
저작권자 © 헬스코리아뉴스 무단전재 및 재배포 금지
